Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine - PubMed (original) (raw)
Review
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine
L F Brown et al. EXS. 1997.
Abstract
VPF/VEGF is a multifunctional cytokine that contributes to angiogenesis by both direct and indirect mechanisms. On the one hand, VPF/VEGF stimulates the endothelial cells lining nearby microvessels to proliferate, to migrate and to alter their pattern of gene expression. On the other hand, VPF/VEGF renders these same microvascular endothelial cells hyperpermeable so that they spill plasma proteins into the extravascular space, leading to profound alterations in the extracellular matrix that favor angiogenesis. These same principles apply in tumors, in several examples of non-neoplastic pathology, and in physiological processes that involve angiogenesis and new stroma generation. In all of these examples, microvascular hyperpermeability and the introduction of a provisional, plasma-derived matrix precede and accompany the onset of endothelial cell division and new blood vessel formation. It would seem, therefore, that tumors have made use of fundamental pathways that developed in multicellular organisms for purposes of tissue defense, renewal and repair. VPF/VEGF, therefore, has taught us something new about angiogenesis; namely, that vascular hyperpermeability and consequent plasma protein extravasation are important--perhaps essential--elements in its generation. However, this finding raises a paradox. While VPF/VEGF induces vascular hyperpermeability, other potent angiogenic factors apparently do not, at least in sub-toxic concentrations that are more than sufficient to induce angiogenesis (Connolly et al., 1989a). Nonetheless, wherever angiogenesis has been studied, the newly generated vessels have been found to be hyperpermeable. How, therefore, do angiogenic factors other than VPF/VEGF lead to the formation of new and leaky blood vessels? We do not as yet have a complete answer to this question. One possibility is that at least some angiogenic factors mediate their effect by inducing or stimulating VPF/VEGF expression. In fact, there are already clear example of this. A number of putative angiogenic factors including small molecules (e.g. prostaglandins, adenosine) as well as many cytokines (e.g. TGF-alpha, bFGF, TGF-beta, TNF-alpha, KGF, PDGF) have all been shown to upregulate VPF/VEGF expression. Further studies that elucidate the crosstalk among various angiogenic factors are likely to contribute significantly to a better understanding of the mechanisms by which new blood vessels are formed in health and in disease.
Similar articles
- Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Dvorak HF, et al. Am J Pathol. 1995 May;146(5):1029-39. Am J Pathol. 1995. PMID: 7538264 Free PMC article. Review. - Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis.
Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Dvorak HF, et al. Curr Top Microbiol Immunol. 1999;237:97-132. doi: 10.1007/978-3-642-59953-8_6. Curr Top Microbiol Immunol. 1999. PMID: 9893348 Review. - Vascular permeability factor (VPF, VEGF) in tumor biology.
Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Senger DR, et al. Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24. doi: 10.1007/BF00665960. Cancer Metastasis Rev. 1993. PMID: 8281615 Review. - Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin.
Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP. Detmar M, et al. J Invest Dermatol. 1997 Mar;108(3):263-8. doi: 10.1111/1523-1747.ep12286453. J Invest Dermatol. 1997. PMID: 9036922 - Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, Brown LF. Abu-Jawdeh GM, et al. Lab Invest. 1996 Jun;74(6):1105-15. Lab Invest. 1996. PMID: 8667614
Cited by
- In vitro biocompatibility and bioactivity of calcium silicate‑based bioceramics in endodontics (Review).
Song W, Li S, Tang Q, Chen L, Yuan Z. Song W, et al. Int J Mol Med. 2021 Jul;48(1):128. doi: 10.3892/ijmm.2021.4961. Epub 2021 May 20. Int J Mol Med. 2021. PMID: 34013376 Free PMC article. Review. - Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro.
Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME. Bell C, et al. In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):533-42. doi: 10.1007/s11626-999-0064-y. In Vitro Cell Dev Biol Anim. 1999. PMID: 10548435 - Conditional deletion of CD25 in the corneal epithelium reveals sex differences in barrier disruption.
Abu-Romman A, Scholand KK, Pal-Ghosh S, Yu Z, Kelagere Y, Yazdanpanah G, Kao WW, Coulson-Thomas VJ, Stepp MA, de Paiva CS. Abu-Romman A, et al. Ocul Surf. 2023 Oct;30:57-72. doi: 10.1016/j.jtos.2023.07.008. Epub 2023 Jul 27. Ocul Surf. 2023. PMID: 37516317 Free PMC article. - Profound effects on vascular development caused by perturbations during organogenesis.
Auerbach R, Auerbach W. Auerbach R, et al. Am J Pathol. 1997 Nov;151(5):1183-6. Am J Pathol. 1997. PMID: 9358741 Free PMC article. Review. No abstract available. - Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.
Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC. Papapetropoulos A, et al. J Clin Invest. 1997 Dec 15;100(12):3131-9. doi: 10.1172/JCI119868. J Clin Invest. 1997. PMID: 9399960 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources